Sumitomo Mitsui Trust Group
PACB icon

Sumitomo Mitsui Trust Group’s Pacific Biosciences PACB Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.29M Sell
7,037,987
-770,593
-10% -$1.38M 0.01% 676
2025
Q4 		$14.6M Sell
7,808,580
-868,978
-10% -$1.67M 0.01% 653
2025
Q3 		$11.1M Sell
8,677,558
-540,897
-6% -$732K 0.01% 676
2025
Q2 		$11.4M Sell
9,218,455
-346,876
-4% -$401K 0.01% 664
2025
Q1 		$11.3M Sell
9,565,331
-613,170
-6% -$941K 0.01% 682
2024
Q4 		$18.6M Sell
10,178,501
-1,687,265
-14% -$3.29M 0.01% 654
2024
Q3 		$20.2M Sell
11,865,766
-774,795
-6% -$1.27M 0.01% 635
2024
Q2 		$17.3M Sell
12,640,561
-183,824
-1% -$371K 0.01% 658
2024
Q1 		$48.1M Sell
12,824,385
-375,990
-3% -$2.2M 0.03% 505
2023
Q4 		$129M Sell
13,200,375
-247,291
-2% -$2.02M 0.1% 218
2023
Q3 		$112M Sell
13,447,666
-202,282
-1% -$2.31M 0.09% 226
2023
Q2 		$182M Sell
13,649,948
-356,567
-3% -$4.33M 0.14% 152
2023
Q1 		$162M Sell
14,006,515
-159,678
-1% -$1.59M 0.12% 178
2022
Q4 		$116M Sell
14,166,193
-225,769
-2% -$1.95M 0.09% 252
2022
Q3 		$83.5M Buy
14,391,962
+46,477
+0.3% +$267K 0.07% 332
2022
Q2 		$63.4M Buy
14,345,485
+324,280
+2% +$1.97M 0.05% 421
2022
Q1 		$128M Buy
14,021,205
+2,106,180
+18% +$24.2M 0.09% 260
2021
Q4 		$244M Buy
11,915,025
+2,567,023
+27% +$61.9M 0.15% 149
2021
Q3 		$239M Buy
9,348,002
+1,215,677
+15% +$36M 0.15% 143
2021
Q2 		$284M Buy
8,132,325
+2,929,012
+56% +$85.2M 0.17% 136
2021
Q1 		$173M Buy
5,203,313
+725,219
+16% +$25.4M 0.11% 207
2020
Q4 		$116M Buy
4,478,094
+361,541
+9% +$6.14M 0.08% 299
2020
Q3 		$40.6M Buy
+4,116,553
New +$23.7M 0.03% 548

Other funds holding PACB

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Sumitomo Mitsui Trust Group's PACB Position: Q1 2026 in Review

Sumitomo Mitsui Trust Group reduced its Pacific Biosciences (PACB) stake by 9.9% in Q1 2026, selling an estimated $1.38M and leaving 7,037,987 shares worth $9.29M. The position accounts for 0.01% of the portfolio, ranked #676.

Sumitomo Mitsui Trust Group first reported a position in PACB in Q3 2020 and has held it in 23 quarters since. The position peaked at $284M in Q2 2021. 229 funds tracked by Wall St. Rank hold PACB as of Q1 2026.

  • Sumitomo Mitsui Trust Group held 7,037,987 shares of Pacific Biosciences worth $9.29M as of Q1 2026.
  • Sumitomo Mitsui Trust Group sold 770,593 Pacific Biosciences shares in Q1 2026, an estimated $1.38M.
  • Pacific Biosciences made up 0.01% of Sumitomo Mitsui Trust Group's portfolio in Q1 2026, its #676 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Pacific Biosciences in Q3 2020 and has held it in 23 quarters since.
  • Sumitomo Mitsui Trust Group's Pacific Biosciences position peaked at $284M in Q2 2021.
  • 229 funds tracked by Wall St. Rank held Pacific Biosciences as of Q1 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q1 2026, filed 30 Apr 2026.